Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Mature Results of a Phase 1-2 Open-Label, Dose-Escalation Study of Intravenous SNS01-T in Patients (pts) with Relapsed or Refractory B-Cell Malignancies

David S. Siegel, MD PhD, Andrew McDonald, MBChB, Nicolas Novitzky, MD PhD, William Bensinger, Michael Craig, MD, Frits van Rhee, MD PhD, Martin Gutierrez, MD, Edward N. Libby, MD, John Thompson, Alice S Bexon, MD, Charles Barranco, Catherine A Taylor, Richard Dondero, Leslie J. Browne, PhD, Michael R. Kurman, MD, John A. Lust, MD PhD

Blood (2014) 124 (21): 4464.

https://doi.org/10.1182/blood.V124.21.4464.4464

Published: 2014

Journal Articles

Prediction of Progression-Free Survival with Brentuximab Vedotin Therapy for Relapsed Hodgkin Lymphoma: A Retrospective Analysis

Anna Houk, BS, MS1, Ajay K. Gopal, MD, Edward N. Libby, MD, Andrei R. Shustov, MD, Damian J. Green, MD, Mary Philip, MD PhD, Johnnie J. Orozco, MD PhD, David G Maloney, MDPhD, Oliver W. Press, MD PhD, Stephen D. Smith, MD

Blood (2014) 124 (21): 3086.

https://doi.org/10.1182/blood.V124.21.3086.3086

Published: 2014

Journal Articles

Failure of Intensified Induction Therapy and Inability to Undergo Stem Cell Transplantation Predict Dismal Outcomes in Relapsed/Refractory MYC + B-Cell Lymphoma

Ryan D. Cassaday, MD, Philip A. Stevenson, MS, Bronwyn H. Bryant, MD, Cecilia Yeung, MD, Brian G. Till, MD, Stephen D. Smith, MD, Edward N. Libby, MD, Andrei R. Shustov, MD, John M. Pagel, MD PhD, Damian J. Green, MD, Mary Philip, MD PhD, Johnnie J. Orozco, MD PhD, Min Fang, MD PhD, Leona Holmberg, MD PhD, William I. Bensinger, MD, David G Maloney, MDPhD, Ajay K. Gopal, MD, Oliver W. Press, MD PhD

Blood (2014) 124 (21): 1731.

https://doi.org/10.1182/blood.V124.21.1731.1731

Published: 2014

Journal Articles

Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of a Novel, First-in-Class Modulator of Eukaryotic Translation Initiation Factor 5A (eIF5A) in Patients (pts) with Relapsed or Refractory B-Cell Malignancies: Data from a Phase 1-2 Study

Alice S Bexon, MD, Michael Craig, MD, David S. Siegel, MD PhD, William Bensinger, Nicolas Novitzky, MD PhD, Andrew McDonald, MBChB, Martin Gutierrez, MD, Edward N. Libby, MD, Frits van Rhee, MD PhD, Jeremy Heidel, PhD, John Thompson, Charles Barranco, Catherine A Taylor, Kathleen A. Donovan, PhD, Laurie L. Moon-Tasson, BA, Leslie J. Browne, PhD, Michael R. Kurman, MD, John A. Lust, MD PhD, Richard Dondero

Blood (2014) 124 (21): 2121.

https://doi.org/10.1182/blood.V124.21.2121.2121

Published: 2014

Journal Articles

Rituximab Maintenance Therapy after Autologous Stem Cell Transplantation Improves Survival of Patients with Mantle Cell Lymphoma

Solomon A. Graf, MD, Philip A. Stevenson, MS, Leona A. Holmberg, MD PhD, Brian G. Till, MD, Oliver W. Press, MD PhD, Thomas R. Chauncey, MD PhD, Stephen D. Smith, MD, Mary Philip, MD PhD, Johnnie J. Orozco, MD PhD, Andrei R. Shustov, MD, Damian J. Green, MD, Edward N. Libby, MD, William I. Bensinger, MD, John M. Pagel, MD PhD, David G Maloney, MDPhD, Yi Zhou, MD PhD, Ryan D. Cassaday, MD, Ajay K. Gopal, MD

Blood (2014) 124 (21): 3985.

https://doi.org/10.1182/blood.V124.21.3985.3985

Published: 2014

Journal Articles

Long Term Follow-up of High-Dose CD20-Targeted Radioimmunotherapy-Based Autologous Transplantation for Patients with Mantle Cell Lymphoma

Ryan D. Cassaday, MD, Philip A. Stevenson, MS, Theodore A. Gooley, PhD, Thomas Chauncey, MD PhD, John Pagel, MD PhD, Brian G. Till, MD, Mary Philip, MD PhD, Johnnie J. Orozco, MD PhD, William I. Bensinger, MD, Leona Holmberg, MD PhD, Andrei R. Shustov, MD, Damian J. Green, MD, Stephen D. Smith, MD, Edward N. Libby, MD, David G Maloney, MDPhD, Lorinda A. Soma, MD, Oliver W. Press, MD PhD, Ajay K. Gopal, MD

Blood (2014) 124 (21): 3967.

https://doi.org/10.1182/blood.V124.21.3967.3967

Published: 2014

NARROW

Mature Results of a Phase 1-2 Open-Label, Dose-Escalation Study of Intravenous SNS01-T in Patients (pts) with Relapsed or Refractory B-Cell Malignancies

Prediction of Progression-Free Survival with Brentuximab Vedotin Therapy for Relapsed Hodgkin Lymphoma: A Retrospective Analysis

Failure of Intensified Induction Therapy and Inability to Undergo Stem Cell Transplantation Predict Dismal Outcomes in Relapsed/Refractory MYC + B-Cell Lymphoma

Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of a Novel, First-in-Class Modulator of Eukaryotic Translation Initiation Factor 5A (eIF5A) in Patients (pts) with Relapsed or Refractory B-Cell Malignancies: Data from a Phase 1-2 Study

Rituximab Maintenance Therapy after Autologous Stem Cell Transplantation Improves Survival of Patients with Mantle Cell Lymphoma

Long Term Follow-up of High-Dose CD20-Targeted Radioimmunotherapy-Based Autologous Transplantation for Patients with Mantle Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Mature Results of a Phase 1-2 Open-Label, Dose-Escalation Study of Intravenous SNS01-T in Patients (pts) with Relapsed or Refractory B-Cell Malignancies

Prediction of Progression-Free Survival with Brentuximab Vedotin Therapy for Relapsed Hodgkin Lymphoma: A Retrospective Analysis

Failure of Intensified Induction Therapy and Inability to Undergo Stem Cell Transplantation Predict Dismal Outcomes in Relapsed/Refractory MYC + B-Cell Lymphoma

Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of a Novel, First-in-Class Modulator of Eukaryotic Translation Initiation Factor 5A (eIF5A) in Patients (pts) with Relapsed or Refractory B-Cell Malignancies: Data from a Phase 1-2 Study

Rituximab Maintenance Therapy after Autologous Stem Cell Transplantation Improves Survival of Patients with Mantle Cell Lymphoma

Long Term Follow-up of High-Dose CD20-Targeted Radioimmunotherapy-Based Autologous Transplantation for Patients with Mantle Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only